Blogger

Groundbreaking Gene Therapy Study Gets The Go-Ahead By The FDA

Calimmune, a small biotechnology company, is  giving people a low dose chemo agent (as conditioning) and then infusing them with stem cells  that have been modified to inhibit the CCR5 receptor and to contain their own built-in HIV fusion inhibitor peptide, thereby blocking two sites that are essential for HIV infection.   The study is …

Groundbreaking Gene Therapy Study Gets The Go-Ahead By The FDA Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

Fw: Hot Topics at TheBody.com’s “Ask the Experts” Forums

From: “News at The Body” <update@news.thebody.com> Date: 06 Nov 2012 19:02:19 -0500 To: <nelsonvergel@yahoo.com> ReplyTo: “News at The Body” <update@news.thebody.com> Subject: Hot Topics at TheBody.com’s “Ask the Experts” Forums If you have trouble reading this e-mail, you can see the online version at: www.thebody.com/topics.html November 6, 2012 Visit the Forums “Hot Topics” Library Change/Update Subscription …

Fw: Hot Topics at TheBody.com’s “Ask the Experts” Forums Read More »

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker

From Natap.org HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker3rd International Workshop on HIV and Aging, November 5-6, 2012, Baltimore Mark Mascolini HIV infection, active HCV infection, and income below $15,000 a year independently predicted shorter telomere length in a study of 229 HIV-positive people and 166 HIV-negative people in …

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker Read More »

Fw: Hot Topics at TheBody.com’s “Ask the Experts” Forums

From: “News at The Body” <update@news.thebody.com> Date: 23 Oct 2012 17:43:17 -0400 To: <nelsonvergel@yahoo.com> ReplyTo: “News at The Body” <update@news.thebody.com> Subject: Hot Topics at TheBody.com’s “Ask the Experts” Forums If you have trouble reading this e-mail, you can see the online version at: www.thebody.com/topics.html October 23, 2012 Visit the Forums “Hot Topics” Library Change/Update Subscription …

Fw: Hot Topics at TheBody.com’s “Ask the Experts” Forums Read More »

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW!

Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! The most effective new therapy ever discovered for the treatment of hepatitis C will never see the light of day unless we are able to convince big pharma giant Gilead Sciences to move forward at once with this development. This treatment combines Bristol-Myers Squibb drug daclatasvir and …

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! Read More »

Fw: HIV Weekly, 17 October 2012

From: hivweekly@nam.org.uk Date: 17 Oct 2012 14:28:05 +0100 To: <nelsonvergel@yahoo.com> ReplyTo: info@nam.org.uk Subject: HIV Weekly, 17 October 2012 Having problems reading this email? View it in your browser >> HIV weekly     17 October 2012 Obesity and health Raltegravir side-effects Hepatitis C treatment Hepatitis C and mental health Editors’ picks from other sources   …

Fw: HIV Weekly, 17 October 2012 Read More »

Scroll to Top